# First-in-Human Study of INT-1B3 in Patients With Advanced Solid Tumors

> **NCT04675996** · PHASE1 · TERMINATED · sponsor: **InteRNA** · enrollment: 25 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** INT-1B3

## Key facts

- **NCT ID:** NCT04675996
- **Lead sponsor:** InteRNA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-18
- **Primary completion:** 2023-03-24
- **Final completion:** 2023-03-24
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** insufficient funding
- **Last updated:** 2024-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04675996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04675996, "First-in-Human Study of INT-1B3 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04675996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*